Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | SDCBP | O00560 | 1/20 | 0.34 |
| ▸ | SDC2 | P34741 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23943398 | 0.91 | MEN1 (0.40) | CASP1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL23943397 | 0.91 | MEN1 (0.40) | CASP1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL24916517 | 0.91 | CASP1 (0.41) | CASP1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL24496722 | 0.91 | KMT2A (0.46) | CASP1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL26445322 | 0.90 | GAA (0.44) | CASP1KMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL24916607 | 0.89 | GAA (0.43) | CASP1KMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL24496736 | 0.89 | CASP1 (0.44) | CASP1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL22854050 | 0.89 | CASP1 (0.44) | CASP1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL23191620 | 0.81 | CASP1 (0.38) | CASP1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL23191619 | 0.81 | CASP1 (0.38) | CASP1KMT2AMEN1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022596-A1 | NEOANTIGEN-ELICITING ANTIBODY DRUG CONJUGATES FOR THE IMMUNOTHERAPY OF CANCER | HURT CLARENCE (US) | 2023-01-26 | — | — | US | disclosed |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022596-A1 | NEOANTIGEN-ELICITING ANTIBODY DRUG CONJUGATES FOR THE IMMUNOTHERAPY OF CANCER | TP53, KLK3, HLA-A | CASP1 2389/4885KMT2A 2152/4885MEN1 804/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | CASP1 1723/4885KMT2A 4104/4885MEN1 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.